Cetus/B-ORG Corp./I-ORG said/O the/O government/O of/O Spain/B-GPE approved/O the/O marketing/O of/O its/O Proleukin/O interleukin/O -/O 2/O drug/O to/O treat/O kidney/O cancer/O ./O
The/O biotechnology/O concern/O said/O Spanish/O authorities/O must/O still/O clear/O the/O price/O for/O the/O treatment/O ,/O but/O that/O it/O expects/O to/O receive/O such/O approval/O by/O year/O end/O ./O
Four/O other/O countries/O in/O Europe/B-LOC have/O approved/O Proleukin/O in/O recent/O months/O ./O
Cetus/B-ORG is/O currently/O trying/O to/O obtain/O federal/O regulatory/O clearance/O for/O U.S./B-GPE distribution/O ./O
